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The human body is colonized by millions of microorganisms named microbiota
that interact with our tissues in a cooperative and non-pathogenic manner. These
microorganisms are present in the skin, gut, nasal, oral cavities, and genital tract. In
fact, it has been described that the microbiota contributes to balancing the immune
system to maintain host homeostasis. The gut is a vital organ where microbiota can
influence and determine the function of cells of the immune system and contributes to
preserve the wellbeing of the individual. Several articles have emphasized the connection
between intestinal autoimmune diseases, such as Crohn’s disease with dysbiosis or an
imbalance in the microbiota composition in the gut. However, little is known about the role
of the microbiota in autoimmune pathologies affecting other tissues than the intestine.
This article focuses on what is known about the role that gut microbiota can play in the
pathogenesis of non-intestinal autoimmune diseases, such as Grave’s diseases, multiple
sclerosis, type-1 diabetes, systemic lupus erythematosus, psoriasis, schizophrenia, and
autism spectrum disorders. Furthermore, we discuss as to howmetabolites derived from
bacteria could be used as potential therapies for non-intestinal autoimmune diseases.
Keywords: microbiota, autoimmune disease, gut, microbiome, skin, CNS
INTRODUCTION
Our body is colonized by millions of microorganisms that can survive in extreme environments
surpassing difficult conditions, such as low pH or low oxygen (Peterson et al., 2015). The
skin, gut, nasal, and oral cavities and genital tract are colonized by hundreds of different types
of microorganisms and are known as “normal flora” or microbiota (Peterson et al., 2015).
Lederberg defined the microbiota in 2001 as “the ecological community of commensal, symbiotic,
and pathogenic microorganisms that share our body space” (Lederberg , 2001). For some authors
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the concept of microbiota comprehends mainly bacteria and
while the concept of microbiota comprehends several different
species among them are bacteria, archaea, fungi and viruses
(Selber-Hnatiw et al., 2017). Recent scientific advances supported
additionally by “omics analyses” have been crucial for the
generation of a large amount of data relative to the composition
of the microbiota (Almonacid et al., 2017). In fact, scientific
progress has allowed the identification of the composition of
the microbiota and the identification of specific microorganisms
that live in the gut (Ferreira et al., 2017). The analysis of
this information has contributed to revealing the complex
relationship between the microbiota and the host. Evidence in
the literature has shown that alterations in the proportion of
these microorganisms can be associated to pathologies affecting
humans (Aarts et al., 2017; Almonacid et al., 2017; Ferreira
et al., 2017). Along these lines, in the past few years several
scientific publications have shown a possible association between
microbiota alterations and autoimmune diseases (Alkanani et al.,
2015; Ma et al., 2015; Miyake et al., 2015; Breban et al., 2017;
Kohling et al., 2017). These pathologies are characterized by
an immune response against the body’s own tissues causing
inflammation and destruction of tissues and/or organs (Nagy
et al., 2015). Autoimmune diseases are especially frequent in
western countries, affecting majorly women (Davidson and
Diamond, 2001). It has been proposed that lifestyle in this
“modern era” can be affecting the microbiota composition
causing a deregulation of the immune system (Berbers et al.,
2017). Evidences in the literature have shown a strong link
between microbiota composition and intestinal autoimmune
diseases, such as Crohn‘s disease and inflammatory bowel disease
(IBD) (Matsuoka and Kanai, 2015; Nishida et al., 2017; Powell
and MacDonald, 2017). However, host gut microbiota seems
also capable of influence autoimmune diseases that target tissues
other than the intestine, including Type 1 diabetes (De Groot
et al., 2017), multiple sclerosis (Hindson, 2017), arthritis (Felix
et al., 2017), and psoriasis (Yan et al., 2017). Interestingly diseases
like schizophrenia and autism are now considered to also have
an inflammatory component suggesting that these ailments could
also be associated to changes in intestinal microbiota (Dickerson
et al., 2017; Vasquez, 2017; Wu, 2017; Yang et al., 2017; Cox and
Weiner, 2018; Kopec et al., 2018). The aim of this review article is
to analyze recent information supporting an association between
gut microbiota composition and non-intestinal autoimmune
diseases.
THE MICROBIOTA THROUGH HUMAN LIFE
An adult of 70 kg in average has around 39 trillion of bacteria
and 30 trillion of human cells (Sender et al., 2016) and at least
20% of the metabolites in the blood are derived from commensal
bacteria (Rook et al., 2017). The gut microbiota consists of about
2,000 different bacterial species (Llorente and Schnabl, 2015)
and most of them reside at the distal intestine (Kamada et al.,
2013b). In general, human gut microbiota is comprised by two
main dominants phyla Firmicutes and Bacteroidetes, which are
susceptible to alterations due to factors such as age, genetics,
diet, environment, and infection (Gill et al., 2006). The neonatal
microbiota is highly different compared to adult microbiota
(Pickard et al., 2017). Neonatal microbiota is strongly influenced
by type of delivery at birth. Thus, a vaginal delivery allows
the colonization of the mother’s gastrointestinal microorganisms
to the neonate, meanwhile in a C-section delivery the infant
will present more microorganisms related to mother’s skin
(Wampach et al., 2017).
Certain data support the notion that bacteria colonization
in humans will begin in the gestation at the womb (Stinson
et al., 2017). Consistently, several reports have detected the
presence of bacterial DNA in the amniotic fluid, umbilical cord,
placenta, meconium, and fetal membranes (Khan et al., 2016;
Stinson et al., 2017; Tschoeke et al., 2017). This evidence is
in contrast with the hypothesis of the sterile womb and that
bacteria colonization in humans begins only at birth or at
breastfeeding (Funkhouser and Bordenstein, 2013). The neonatal
microbiota initially will resemble very much to individual
maternal microbiota (Wampach et al., 2017). During the
following years, the microbiota will be shaped and changed by
nutritional, physiological, and/or pathological events occurring
through life (Chu et al., 2016).
Evidence suggests that a proper microbiota homeostasis is
required for the maturation of central nervous system (CNS),
as well as the immune system during different developmental
stages, such as infancy, adolescence, and adulthood (Rook et al.,
2017). Certain microorganisms included in the microbiota will
contribute to an appropriate development of various human
tissues and organs. However, othermicroorganism could increase
the susceptibility to suffering certain pathologies (Berbers et al.,
2017). Therefore, the diet is an important factor that can lead
to changes in the microbiota composition (Cui et al., 2017).
It has been reported that only 24 h are sufficient to alter the
composition of the microbiota after a change in the diet of an
individual (Wu et al., 2011). For example, high fat diets increase
the presence of enterotypes, such as Bacteroides meanwhile a
fiber-rich diet increases the amount of the Prevotella genus (Wu
et al., 2011). It has been shown that inappropriate changes in
the microbiota composition, known as dysbiosis, could cause
harmful consequences to the host (La Fata et al., 2017). For
example dysbiosis has been reported for patients suffering from
type I and type II diabetes, IBD and colorectal cancer (CRC)
(Peterson et al., 2015). Because it would be of importance to
understand how the microbiota composition can impair the
wellness of the host, significant research efforts are currently in
place to develop new treatments for these pathologies based on
restoring a normal microbiota composition.
THE INTESTINAL BARRIERS FOR THE
MICROBIOTA
The gut has developed different mechanisms to ensure a
beneficial intestinal microbiota composition, as well as for
regulating microbiota overgrowth and restricting pathogen
colonization (Llorente and Schnabl, 2015; Gensollen et al., 2016).
It is thought that the gut can produce an intestinal barrier by
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secretingmucus and pro-inflammatorymolecules that contribute
to the establishment of innate and adaptive immunity (Feng and
Elson, 2011).
Intestinal epithelial cells are the first constituents of the gut
barrier and they cover the intestinal lumen and separate the
gut microbiota from the immune system (Farhadi et al., 2003;
Feng and Elson, 2011). Epithelial cells are maintained together by
tight junctions (TJs), adherents junctions (AJ), and desmosomes
(Hartsock and Nelson, 2008). TJs are multiprotein complexes
comprised of integral membrane proteins, such as claudins,
occludins, and junctional adhesion molecules (Hartsock and
Nelson, 2008). The TJs regulate the passing of solutes and fluids
through the epithelial cells by passive paracellular diffusion (Choi
et al., 2017). As part of the epithelial cell barrier are goblet
cells, which secrete glycoproteins to the lumen forming an inner
mucus layer that is closer to epithelium and an outer mucus
layer that is in contact with bacteria (Hooper and Macpherson,
2010). Additionally, epithelial cells can secrete antimicrobial
proteins, such as defensins, cathelicidins, and C-type lectins
(Chairatana and Nolan, 2017). These molecules contribute at
controlling bacterial growth by either enzymatically degrading
their cell wall, disrupting the inner membrane or depriving
bacteria from essential heavy metals (Mukherjee and Hooper,
2015). Additionally, enterocytes, enteroendocrine cells, globet
cells, and Paneth cells can also produce antimicrobial proteins
contributing to the antimicrobial activity (Chairatana and Nolan,
2017).
The three main lymphoid structures of gut immune system
that locate at the mucosa are: (1) the Peyer’s patches (PP), which
is the mucosa-associated lymphoid tissue that can be found
in clusters; (2) the lamina propria (LP) located as an isolated
lymphoid tissue where effector lymphocytes secrete cytokines
and immunoglobulins; and (3) the epithelium layer in which
intraepithelial resident lymphocytes can be found (Richards et al.,
2016; Shi et al., 2017). The secretion of IgA is considered to be an
antimicrobial agent that is accomplished by the help of dendritic
cells (DC) from the PP. IgA interacts with bacteria impeding
their adhesion to epithelial cells and inhibiting bacterial motility
(McGuckin et al., 2011).
The gut microbiota is tightly associated and has constant
communication with the mucosal immune system. It is thought
that the mucosal immune system limits the invasion of tissues
by the normal flora, which entails a high microbial diversity as
well as potential pathogens that could have been ingested with
the diet (Hooper and Macpherson, 2010). Such a function is in
part carried out by DCs located at the mucosal surface where
they uptake antigens and prime lymphocytes. DCs can directly
sample normal flora and pathogenic bacteria (Kelsall, 2008).
Despite all of these barrier mechanisms, bacteria can find ways
for trespassing them and go across the epithelial layer triggering
bacteria killing mechanisms. Rapidly, trespassing bacteria suffer
phagocytosis and elimination by the LP macrophages (Kelsall,
2008).
Activated DCs can promote the differentiation of T cells to
regulate immune tolerance (Shi et al., 2017). In fact, there is a
high content of T cells at the intestinal mucosa that can be divided
in two major subpopulations known as type A or conventional
(TCRαβ) located at the PPs and mesenteric lymph nodes and
type B or non-conventional (TCRγδ) that can be found almost
exclusively at the epithelium (Van Wijk and Cheroutre, 2010).
Naïve T cells become activated into effector helper T cells (Th)
by mainly differentiating into: (1) Th1 cells that contribute to the
elimination of intracellular pathogens; (2) Th2 cells that protect
against parasites and mediate allergic reactions; or (3) Th17 cells
that contribute to the clearance of foreign pathogens (Geremia
et al., 2014). Intestinal DCs can also regulate the differentiation
of T cells to regulatory T cells (Tregs). The role of Tregs is to
reduce and control the immune response in part by suppressing
the activation and proliferation of T helper cells through the
secretion of anti-inflammatory cytokines (O’garra and Vieira,
2004). Several studies support the notion that an alteration of
the balance between T helper and Treg cells can be closely
associated to intestinal autoimmune pathologies (Fasching et al.,
2017; Figure 1).
MODULATION OF T CELL
DIFFERENTIATION BY THE MICROBIOTA
Microbiota members can regulate the immune response through
secretion of metabolites, such as short-chain fatty acids (SCFA).
SCFAs are produced in the colon by the microbiota through
fermentation of non-digestible carbohydrates including cellulose
or inulin among others (Chen et al., 2015). The main products
are acetate, propionate and butyrate, which are absorbed by the
colon (Rios-Covian et al., 2016). While butyrate acts as an energy
source for epithelial cells (Jung et al., 2015) and facilitates tight
junction assembly (Peng et al., 2009), acetate and propionate are
substrates for gluconeogenesis and lipogenesis in the liver and
other peripheral organs (Rios-Covian et al., 2016).
SCFAs can modulate the intestinal immune response
(Tremaroli and Backhed, 2012) by regulating T cell
differentiation (Cavaglieri et al., 2003), epithelial barrier
function, production of antimicrobial peptides, and the secretion
of pro-inflammatory mediators (Johnson-Henry et al., 2014).
Administration of butyrate in an animal model of colorectal
colitis ameliorates the symptoms by increasing the percentage of
Tregs and the production of IL-10 and IL-12 in peripheral blood,
with an concomitant decrease of RORγt (a Th17 biomarker),
IL-17 and IL-23 levels (Zhang et al., 2016). Furthermore,
the addition in vitro of butyrate to human peripheral blood
mononuclear cells (PBMCs) increased the differentiation of
Tregs suggesting for this molecule a regulatory role in Treg/Th17
balance that influences the immune response (Zhang et al.,
2016). Administration of SCFAs has been used in animal models
of experimental autoimmune encephalomyelitis (EAE). It was
observed that the oral administration of SCFAs butyrate, acetate,
and propionate could significantly decrease EAE clinical score
in mice (Mizuno et al., 2017). In these experiments, propionate
showed the higher capacity to protect animals from the
development of EAE (Mizuno et al., 2017) Interestingly, while
treatment with propionate increased the frequency of Tregs
in lymph nodes, treatment with butyrate did so in the spleens
(Mizuno et al., 2017). These results reinforce the notion that
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FIGURE 1 | Microbiota and pathogen control mechanisms of the gut immune system. The immune system of the gut has to deal with wide diversity of microbiota and
pathogens. Thus, the immune system will help to establish a beneficial microbiota composition at the gut. Different mechanisms of the gut immune system have been
discovered that control microbiota overgrowth and pathogens invasion. The gut immune system locates in the mucosa layer of the intestine mainly at the epithelium
layer and Peyer’s patches at the lamina propia. Enterocytes, enteroendocrine cells, globet cells, and Paneth cells, located in the intestinal epithelial layer, secrete
antimicrobial peptides like defensins. It has been shown that defensins are produced in the course of innate immune defense to activate the adaptive immune
response. Another mechanism to control microbiota is the secretion of IgA which is accomplished by dendritic cells (DC). IgGA by interacting with bacteria impedes
their adhesion and inhibits bacteria motility. DCs are localized at mucosal surfaces in antigen uptake sites and at inductive lymphoid tissue; they can directly sampling
the normal flora and pathogenic bacteria. In the mesenteric lymph node DCs can promote differentiation of T cells, to regulate immune tolerance. Once T cells are
activated they differentiate to T helper cells (Th), like Th1, Th2, or Th17 cells. Intestinal DCs will also regulate the differentiation of T cells to T regulatory (Treg) cells. Treg
cells have the capacity to suppress the activation and proliferation of Th cells by the secretion of anti-inflammatory cytokines.
SCFAs from the intestine can regulate systemic inflammation
that is mediated by lymphocytes.
Hashimoto et al. by using Ace2 knockout mice showed
that a protein-free diet alters intestinal immunity (Hashimoto
et al., 2012). Angiotensin converting enzyme-2 (ACE2) is a
key regulatory enzyme of the renin-angiotensin system (RAS)
as it catalyzes the conversion of angiotensin II (Ang II) to
angiotensin 1–7 (Ang 1–7) the latter can bind the G-coupled
protein Mas receptor inducing vasodilatation contrasting the
effects of the binding of Ang II to its receptor AT-1 that promotes
vasoconstriction and hypertension (Perlot and Penninger, 2013).
ACE2 knockout male mice or Ace2−/y mice (Ace deficient at
the × chromosome) induced with colitis and protein-deprived
showed increased infiltration, ulceration, weight loss and higher
diarrhea scores, as well as decreased serum levels of tryptophan
(Trp) (Hashimoto et al., 2012). Trp is an essential amino
acid for mammals and can only be obtained through the diet
(Badawy, 2017). These knockout mice supplemented with Trp
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significantly improved colitis symptoms (Hashimoto et al., 2012).
Additional analyses showed that these mice display an altered
gut microbiota composition and an increase production of
antimicrobial peptides, as compared to Trp-supplemented mice
(Hashimoto et al., 2012).
Moreover, it has been observed that the microbiota produces
catabolites from Trp or Trp-indole derivatives, such as Indole
3-acetamide, indole-3-acetic acid and indole-3-lactic acid and
modulates themucosal immune response through IL-22, which is
produced by innate lymphoid cells 3 (ILC3) (Zelante et al., 2013).
Consistently with these findings, Lamas et al. showed that the
colitis associated knockout mice for Card9 display a microbiota
dysbiosis (Lamas et al., 2016). An adaptor protein involved in
the immune response against fungi dysbiosis (Etienne-Mesmin
et al., 2017). Authors showed that Card9 knockout mice missed
a Trp-metabolizing bacterium. Thus, the consequence is that
these mice had low content of indole derivatives, which are
important for the production of IL-22 by the ILC3 and T cells
at the mucosa. Low levels of IL-22 generate a pro-inflammatory
environment (Lamas et al., 2016), because this cytokine has anti-
inflammatory properties and belongs to the IL-10 cytokine family
(Parks et al., 2015). IL-22 participates in host defense against
extracellular pathogens by eliciting innate defensive mechanisms
that promote the expression of antimicrobial peptides at mucosal
surfaces (Rutz et al., 2013) and is also involved in tissue repair by
enhancing epithelial cell proliferation (Aujla and Kolls, 2009).
Additionally, IL-22 can influence intestinal epithelial cell
glycosylation by inducing the expression of fucosyltransferase
2 (Fut2) that catalyzes the fucosylation of membrane proteins,
a post translational modification needed for protection against
enteric pathogens, such as S. typhimurium (Okumura and
Takeda, 2017). Recent data support the notion that microbiota
has immune-modulatory properties, however little is known
about the identification of the specific bacteria genera responsible
for the phenotype and also few is known at molecular level for
which mechanisms these bacteria modulate the inflammatory
state of the intestine. So far, it has been described that the
presence of polysaccharide A (PSA) in the gut commensal
Bacteroides fragilis induces the secretion of IL-10 by Tregs, which
in turn decreases inflammation in the gut and in distant tissues,
such as the brain (Ochoa-Reparaz et al., 2010; Dasgupta et al.,
2014). These findings highlight the role of metabolites produced
by the intestinal microbiota to modulate inflammation and their
potential use as a therapeutic tool to treat inflammatory and
autoimmune diseases.
WHAT DO WE KNOW ABOUT THE ROLE
OF THE MICROBIOTA IN NON-INTESTINAL
AUTOIMMUNE DISEASES?
Autoimmune Diseases
Autoimmune diseases are pathologies characterized by an
inappropriate immune response against own tissues and
molecules that results in tissue-specific or systemic inflammation
that leads to organ damage and malfunction (Rose and Bona,
1993; Marmont, 1994). Causes for autoimmune disease are
multifactorial and range from genetic predisposition to the
exposition of environmental agents, such as infectious agents,
xenobiotics, drugs, or stress (Davidson and Diamond, 2001).
The disease progresses from initial naive lymphocyte activation
to a chronic state characterized by an increase in the number
of autoantigens targeted by T cells and antibodies. Activated
autoreactive B cells can function as antigen presenting cells for
novel peptides and express co-stimulatory molecules. Antigens
are processed and presented to naive T cells leading to the
activation of additional autoreactive B cells that present new
epitopes up to a point in which there is autoreactivity to a large
number of autoantigens (Lanzavecchia, 1995; Liang andMamula,
2000). The production of autoantibodies induces damages to
tissues by the formation of immune complexes, cytolysis, or
phagocytosis of target self-cells and interfering with proper tissue
and cellular functions (O’Garra et al., 1997). Although there are
several autoimmune diseases, in this review we will focus on
non-intestinal autoimmune disorders, for intestinal autoimmune
diseases, please refer to other reports (Gallo et al., 2016; Blander
et al., 2017; Passos and Moraes-Filho, 2017).
Graves’s Disease and Hashimoto’s
Thyroiditis
The Grave’s disease (GD) is an autoimmune disease characterized
by the targeting of antigens derived from the thyroid
gland. In GD there are autoantibodies against the thyroid
stimulating hormone receptor (TSHR) (Kristensen, 2016).
These autoantibodies activate the TSHR inducing the synthesis
and secretion of thyroid hormones by the thyroid gland and
causing hyperthyroidism. GD is the most common cause of
hyperthyroidism and is more frequently observed in women
than in men (Pokhrel and Bhusal, 2017). Shor et al. evaluated the
prevalence of gastrointestinal auto antibodies in patients with
Hashimoto’s thyroiditis and Grave’s disease (Shor et al., 2012).
These are anti-gliadin antibodies (AGA), tissue transglutaminase
(tTG) and anti Saccharomyces cerevisiae antibodies (ASCA).
In particular ASCA have proven to be sensitive and highly
specific for Crohn’s disease. ASCA antibodies were highly
prevalent in patients with GD (Shor et al., 2012). Analysis of fecal
samples from GD patients showed an increased content of yeast
supporting Schor’s analyses (Covelli and Ludgate, 2017). It has
also been observed the presence of antibodies against Yersinia
enterocolitica and to Helicobacter pylori, but these responses vary
among patients and are not observed in all the analyzed patients
(Kohling et al., 2017). Next-generation sequencing projects
intended to analyze and identify bacteria species in patients with
GD. Using a TSHR immunized mouse model, it was observed an
alteration of immunized animals when compared to controls. In
humans, this modification is not fully observed, so far it has been
observed in a small number of patients a significant decrease of
the Bacteroides genus (Indigo, 2017). These are the first reports
associating the gut microbiota and GD; therefore additional
work must be accomplished to better understand the influence
of the gut microbiota on the development of GD.
Hashimoto’s thyroiditis (HT) is an autoimmune disease that
is characterized by the infiltration of mononuclear cells in
Frontiers in Microbiology | www.frontiersin.org 5 March 2018 | Volume 9 | Article 432
Opazo et al. Microbiota and Non-intestinal Autoimmune Diseases
the thyroid, together with the production of autoantibodies
against thyroglobulin and thyroid peroxidase (TPO) (Antonelli
et al., 2015). It is thought that environmental factors, such as
diets higher in iodide, contribute to the etiology of HT (Rose
et al., 2002). Recently, research efforts have focused on the
involvement of microbiota in the pathogenesis of autoimmune
diseases. The transfer of microbiota from conventional rats to
specific pathogen free (SPF) rats increased the susceptibility of
the latter to experimental autoimmune thyroiditis (Penhale and
Young, 1988), which provides further support for an influence
of the microbiota during HT pathogenesis. The use of the
probiotic mixture (VSL#3TM) has been successful to reduce
the susceptibility to developing autoimmune diseases, such as
Type 1 diabetes and colitis by enhancing the production of IL-
10 in Peyer’s patches and the spleen (Calcinaro et al., 2005;
Di Giacinto et al., 2005). Along these lines, it was important
to explore whether probiotics could have a positive effect on
HT. Contrarily to what was initially thought, the use probiotic
strains of Lactobacillus rhamnosusHN001, Bifidobacterium lactis
HN019, and L. rhamnosus GG failed to improve the disease
outcome in a mouse model for autoimmune thyroiditis (Zhou
and Gill, 2005). It has been demonstrated that a dysbiosis
state can alter the epithelial barrier permeability leading to
a condition known as “leaky gut” (Vaarala et al., 2008). At
the histologic level, this is observed as morphological changes
in epithelial cells and lymphocyte infiltration (Fritscher-Ravens
et al., 2014). Interestingly, a similar observation has been made
in patients with HT, in which both the space of two adjacent
microvilli and the microvilli thickness are significantly increased.
Furthermore, these patients were also evaluated for functional
mucosal alterations using a lactulose/manitol test showing an
increase in the recovery of lactulose/mannitol, which is consistent
with the histological observations (Sasso et al., 2004). These data
suggest that the microbiota and the epithelial barrier play an
important role of during the pathogenesis of HT.
Type I Diabetes
Type 1 diabetes (T1D) is the most prevalent autoimmune disease
in young people (<20 years), with a peak at 10–14 years old
(Maahs et al., 2010) being more common in boys than in girls
(Atkinson et al., 2014). The incidence of T1D is very variable
worldwide, being higher in Europeans countries probably due to
environmental factors (Xie et al., 2014) T1D is characterized by
a T cell-mediated (CD4+ and CD8+) destruction of β pancreatic
cells (Atkinson et al., 2014). There are three major auto antigens
associated to T1D, which are insulin, GAD65 (glutamic acid
descarboxylase, 65 kDa isoform), and IA2 (Insulin autoantigen 2)
(Ounissi-Benkalha and Polychronakos, 2008). The presence of
antibodies specific for these antigens has been observed in the
serum of T1D patients (Miao et al., 2007). A classical trio of
symptoms characterizes T1D, which are polydipsia, polyphagia,
and polyuria, accompanied by an overt hypoglycemia (Atkinson
et al., 2014). All of them are used as hallmarks for T1D diagnosis
in high-risk individuals, such as children and adolescents (Leslie,
2010).
The 60% of patients suffering from T1D has been attributed
to a genetic cause (Ounissi-Benkalha and Polychronakos, 2008).
The 50% of heritability of T1D is attributed to the human
leukocyte antigen (HLA) alleles located in chromosome 6 and
the rest is to non-HLA loci (Barrett et al., 2009; Redondo et al.,
2017). It has been reported that are at least 40 non-HLA loci
such INS, CTLA4, PTPN22, and IL2RA can contribute to disease
susceptibility (Barrett et al., 2009). Moreover, T1D can also be
triggered by environmental factors, such as cesarean or vaginal
birth, diet, early infections in life etc. (Rewers and Ludvigsson,
2016). Experimental evidence has shown that the intestinal
microbiota could induce T1D by priming the immune system at
an early postnatal period (Endesfelder et al., 2016).
The first evidence linking the gut immune system and T1D
derives from animal models. Non-obese diabetic (NOD) mice
fed with regular commercial cereal-based chow and mice fed
with a 10% casein-based diet presented the highest rates of
T1D among the experimental groups (Elliott et al., 1988). These
rates (26.9% cereal-based chow vs. 19.1% casein-rich diet) were
significantly higher than the expected for this type of mice, which
normally develop insulin-dependent diabetes at 200–250 days
of age. Authors observed that the incidence of T1D in these
mice was due to the 10% of casein in this diet, interestingly this
percentage corresponds to the percentage of casein in cow milk
(Elliott et al., 1988). Another important observation in children
suffering T1D was the presence of antibodies against bovine
serum albumin, a protein also contained in cow milk (Savilahti
et al., 1988; Karjalainen et al., 1992; Saukkonen et al., 1996). These
two observations support the notion that the diet could trigger
the development of T1D, due that it contains potential antigens
that will prime the immune system (Mejia-Leon and Barca, 2015;
Rewers and Ludvigsson, 2016; Virtanen, 2016).
The notion that antigens derived from the diet can prime
the immune system, suggests that the immune system is in
contact with antigens and the intestinal permeability must be
altered. In fact, there is evidence supporting a relationship
between T1D and high intestinal permeability (Vaarala, 2008;
Li and Atkinson, 2015; Maffeis et al., 2016). A study
performed in 46 non-celiac T1D patients showed a significant
increase of intestinal permeability as compared to healthy
controls (Secondulfo et al., 2004). Authors performed electronic
transmission microscopy (TEM) analyses over intestinal biopsies
from non-celiac T1D patients. They observed a partial decrease
in the microvilli together with morphological alterations
at the tight junction domains (Secondulfo et al., 2004).
Another study showed that T1D patients have high intestinal
permeability measured as the urine levels of lactulose and
mannitol 5 h after ingestion and high levels of zonulin in
the serum (Sapone et al., 2006). Zonulin is a protein that
can regulate intestinal permeability by disassembling tight
junctions (Fasano et al., 2000). Studies performed in Biobreeding
diabetes-prone (BBdp) rats, widely used as an animal model
for studying human T1D (Bortell and Yang, 2012), showed
increased intestinal permeability (Meddings et al., 1999). Using
this animal model Neu et al. found in the small intestine
of these animals a high number of globet cells and high
intestinal mucus secretion before the onset of the disease,
reflecting an inflammatory response at the intestine (Neu et al.,
2005).
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Other studies have found that intestinal microbiota could
increase the probability to develop T1D. Studies performed
in non-obese diabetic (NOD) mice at young age, when these
animals are prediabetic, were infected by an oral gavage with
wild type C. rodentium showed higher intestinal permeability,
developed earlier insulitis (Lee et al., 2010) and showed an
increased lymphocytic infiltration at the pancreas Langerhan’s
islets (In’t Veld, 2011). These authors showed that the mutant
strain of C. rodentium that lacks the ability to disrupt
the intestinal barrier was unable to induce insulitis (Lee
et al., 2010). Maffeis et al. observed in Italian T1D affected
children an increased intestinal permeability that correlates
with alterations in the microbiota composition (Maffeis et al.,
2016). Interestingly, the authors found three microbial markers
(D. invisus, G. sanguinis, and B. longum) highly represented in
T1D affected children as compared to healthy controls (Maffeis
et al., 2016). Furthermore, it has been observed that bio-breeding
diabetes-resistant (BBDR) rats present more probiotic bacteria,
such as Bacterioides, Eubacterium, and Ruminococcus (Roesch
et al., 2009). It has also been observed in humans that the
Bacteroidaceae family is over-represented in children with T1D
together with a decrease of intestinal microbiota dominant
species as Bifidobacterium adolescentis and B. pseudocatenulatum
(De Goffau et al., 2013). Microbiota composition can be
influenced by age, with major changes observed at early ages
(Koenig et al., 2011; Arrieta et al., 2014; Rodriguez et al.,
2015). Kostic et al. described that the microbiota of genetically-
predisposed infants from 3 to 36 months old, based on HLA
genotyping, has reduced alpha diversity and overabundance of
Blautia, Rikenellaceae, Ruminococcus, and Streptococcus genera
(Kostic et al., 2015). In contrast, Maffeis et al. (2016) showed
that D. invisus was completely absent in this samples indicating
that there is still contradictory data regarding the microbiota
composition in T1D patients.
Multiple Sclerosis
Multiple sclerosis (MS) is the most common autoimmune disease
that has the CNS as a target (Reich et al., 2018). The immune
system in theMS patients reacts against proteins that are found in
myelin and neurons inducing axonal damage and neuronal death
(Lemus et al., 2018). The MS patient develops several symptoms
that lead to chronic disability including cognition impairment,
loss of motor control, and sensitivity (Yong et al., 2017). Several
reports have shown that MS patients have dysbiosis at the
intestinal microbiota and it has been proposed that MS patients
could have a specific type of microbiome (Chen et al., 2016;
Probstel and Baranzini, 2017; Shahi et al., 2017; Tremlett and
Waubant, 2017). It was shown that MS patients have a relatively
low abundance of the Bacterioides, Parabacteroides, Prevotella,
and Lactobacillus genera and an increased abundance of
Akkermansia, Blautia, Ruminococcus, and Bifidobacterium (Jangi
et al., 2016; Freedman et al., 2017). Interestingly, Akkermansia is
a mucin-degrading microorganism that transforms mucin into
SCFAs, suggesting that this microorganism might be trying to
compensate the inflammatory state of the MS patient (Derrien
et al., 2004, 2011). Cekanaviciute et al. found that samples of
gut microbiome from MS patients impaired the differentiation
of T cells to CD25+FoxP3+ Treg cells (Cekanaviciute et al.,
2017). These authors found that MS patients have a high
presence of the Akkermansia genus, specifically A. calcoaceticus
and A. muciniphila (Cekanaviciute et al., 2017). Further, it was
observed that PBMCs from healthy donors showed an increased
differentiation into effector T cells as compared to Treg cells,
when exposed to A. calcoaceticus extracts from MS patients
(Cekanaviciute et al., 2017). Once PBMCs are exposed to A.
muciniphila extracts from MS patients the differentiation of T
cells inclined toward to Th1 cells, suggesting that the microbiota
of MS patients has a pro-inflammatory effect (Cekanaviciute
et al., 2017).
There are several animal models to study MS, one of
them is the experimental autoimmune encephalomyelitis (EAE)
(Robinson et al., 2014). EAE has the advantage of reproducing
most of the symptoms observed in humans and disease is
mediated by T cells, as it is the case for MS patients (Stromnes
andGoverman, 2006). The induction of EAE in rodents generates
a T cell-mediated response, mainly of Th1 and Th17 types
(Kleinewietfeld and Hafler, 2013). Interestingly, the function
these cells is influenced by the composition microbiota (Wu
and Wu, 2012). It has been shown that in normal conditions
commensal microorganisms, such as segmented filamentous
bacteria can activate these cells to keep a healthy immune
response (Ivanov et al., 2009). Noteworthy, Lee et al. showed
that the germ-free mice were more resistant to EAE (Lee et al.,
2011). The authors observed that some of these mice did not
develop symptoms, while and developed only mild symptoms
and had a shorter period of EAE (Lee et al., 2011). Experiments
of microbiota transfer from specific pathogen free mice (SPF)
mice to germ-free mice enhanced the EAE symptoms in germ-
free mice, supporting the notion that microbiota can influence
the immune response during EAE (Lee et al., 2011).
Other studies have found that the microbiota can alter the
ratio of cells that play important roles during autoimmune
diseases, such as effector T cells vs. Tregs (Molloy et al., 2012;
Kosiewicz et al., 2014). For example, in vitro re-stimulation with
MOG35−55 of T cells from germ-free mice and SPF mice that
have been previously immunized with MOG/CFA showed in SPF
mice an increased secretion of IFNγ and IL-17, as compared to
germ-free mice (Lee et al., 2011). Germ-free mice have increased
frequencies of Tregs at day 8th before the onset of EAE and
at day 15 at the peak of EAE symptoms (Lee et al., 2011).
Recently, it was reported that EAE could be induced in mice
that received microbiota fromMS patients (Berer et al., 2017). By
using next-generation sequencing analyses it was shown that the
microbiota composition of MS patients has a low content of the
Sutterella genus (Berer et al., 2017). It has been observed that this
bacterium plays a beneficial role in patients that suffer from IBD
(Morgan and Harris, 2015). There is evidence that Bacteroides
can be beneficial for maintaining the homeostasis in models
of intra-abdominal sepsis and experimental colitis (Tzianabos
et al., 1995; Pagliuca et al., 2016). This seems to be the case for
B. fragilis, as its polysaccharide (PSA) induces IL-10 secretion by
Tregs (Ochoa-Reparaz et al., 2010). In fact, oral treatment with
purified Bacterioides fragilis PSA has been shown to be beneficial
because it reduces EAE scores, demyelination, IFNγ, and IL-17
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and increases T cells conversion to Tregs and the content of
IL-10 (Ochoa-Reparaz et al., 2010). Oral immunization with an
oral vaccine of attenuated Salmonella typhimurium expressing
the colonization factor antigen I (CFA/I) of Enterotoxigenic
Escherichia coli (ETEC) to mice that suffer EAE decreased the
EAE scores showing a decreased infiltration of TCD4+ cells in
the spinal cord (Jun et al., 2005). CFA/I plays an important role
in the attachment of ETEC to the intestinal epithelia an important
step for diarrhea pathogenesis (Li et al., 2009).
The question as to how the microbiota modulates de immune
response in the MS and/or EAE remains to be addressed. Rumah
et al. showed that bacteria metabolites could modulate the
immune response (Rumah et al., 2013). These authors isolated
a strain of Costridium perfringens type B bacillus from a woman
that suffered MS and showed ovoid lesions at the corpus callosum
(Rumah et al., 2013). By using a mouse model it was shown
that protoxin (a protein secreted by this strain) caused BBB
disruption (Finnie, 1984) and binds to myelin in the CNS
inducing oligodedrocyte death, as observed in frozen sections
of mouse retina (Rumah et al., 2013). Farrokhi et al. found that
serum from MS patients has low levels of the lipid 654, this
lipopeptide is secreted by commensal intestinal Bacteroidetes in
healthy people (Farrokhi et al., 2013). It has been reported that
the lipid 654 could work as a ligand for the human toll-like
receptor 2 (TLR2), thus it could contribute at down-regulating
innate immunity (Clark et al., 2013). The work of Farrokhi
suggests that low levels of lipid 654 could be used as a biomarker
of MS, however further research is required to demonstrate that
this diagnostic approach would be accurate.
Evidence derived from the EAE model suggests that SCFAs
can improve and balance the immune response. Mizuno et al.
observed that the oral administration of propionate decreased
EAE clinical scores and increased Tregs at the lymph nodes, thus
it could favor the suppression effect of Tregs (Mizuno et al.,
2017). Additional interesting work has provided evidence that
supports the notion that the first symptoms of EAE begins at
the intestine (Nouri et al., 2014). Nouri et al. in their article
showed that there is an unbalance of Treg/Th17 toward Th17
pro-inflammatory response at the intestine (Nouri et al., 2014)
Authors also showed an increased intestinal permeability, altered
intestinal morphology across the small intestine characterized
by depth crypt, gross mucosal thickness, and high expression
of zonulin (Nouri et al., 2014). Summarizing, the evidence
available in the literature suggests that intestinal microbiota could
potentiate or modulate the immune response of MS or EAE
specifically the ration or balance of Treg/Th17.
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune
disease with unknown etiology that affects predominantly
women. SLE is characterized by the presence of hyperactive and
aberrant antibody response to nuclear and cytoplasmic antigens
(La Paglia et al., 2017). Regarding the influence of microbiota
over SLE development, microbiota composition analyses showed
that SLE patients display intestinal dysbiosis. A decrease in the
Firmicuteswith an increase of the Bacteroides phyla was observed
(Hevia et al., 2014). These bacteria are the most abundant
components of the human microbiota and the same pattern
has been observed in patients with Crohn’s disease (Qin et al.,
2010). Mouse models of lupus showed differences in microbiota
composition, as compared to control mice. Females showed a
more accelerated development of the disease that was associated
with decreased levels of Lactobacillaceae and increased levels of
Lachnospiraceae families (Zhang et al., 2014). Treatment with
probiotics composed by Lactobacillaceae members has been
used as anti-inflammatory therapies given its anti-inflammatory
properties (Jirillo et al., 2012). Lopez et al. observed the influence
of the microbiota over T cell differentiation in healthy and SLE
patients (Lopez et al., 2016). These authors found an increase in
lymphocyte activation and differentiation toward Th17 in SLE
patients (Lopez et al., 2016). Even though, there is still no clarity
about the role of microbiota in the development of SLE, the
evidence suggests that the dysbiosis observed in the SLE patients
could be related to this disease.
Psoriasis, Psoriasis Arthritis, and Other
Skin Related Autoimmune Pathologies
The literature provides evidence for an association between
intestinal microbiota with skin autoimmune diseases (Scher et al.,
2015; Eppinga et al., 2016; Forbes et al., 2016; Zakostelska
et al., 2016). Intestinal-related autoimmune diseases like Crohn’s
disease is a known comorbidity of psoriasis, patients with
psoriasis have a 2.9-times higher risk of developing Crohn’s
disease as compared to the general population as well as
Crohn’s disease patients have a 7-times higher risk of developing
psoriasis (Oliveira Mde et al., 2015). There is increasing evidence
supporting a role of intestinal dysbiosis as a factor in the
pathogenesis of Crohn’s disease (Kaur et al., 2011) and this might
as well be related to psoriasis pathology.
Another important comorbidity of psoriasis is psoriatic
arthritis, which is a type of chronic spondyloarthritis with
unknown etiology. A recent study characterized the composition
of gut microbiota in patients with psoriatic arthritis, patients
with psoriasis and healthy controls. The gut microbiota profile
of both groups showed decreased bacterial diversity and a
reduced relative abundance of some bacterial taxa as compared
to healthy controls, such as Akkermansia, Ruminococcus,
and Pseudobutyrivibrio. It is important to highlight that the
microbiota profile of psoriatic arthritis resembled that published
for patients with IBD, a finding that further supports a possible
role for the gut microbiota in this skin disease (Scher et al.,
2015). The directionality of this relationship remains poorly
understood, but it opens a new and interesting research field.
Other skin diseases related to intestinal dysbiosis are
scleroderma and vitiligo. In scleroderma (also known as systemic
sclerosis) themajority of patients experience gastrointestinal tract
dysfunction that might be related to gut microbiota composition.
A study performed by Volkmann et al. (2017) shows a different
microbial composition between two different cohorts of patients
with systemic sclerosis and healthy controls. Firmicutes showed a
significantly increased abundance in systemic sclerosis patients
(63.5 and 42.8%) compared to healthy controls (33%). In
contrast, Bacteroidetes decreased in one of the cohorts (21.3%) as
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compared to healthy controls (63.2%). This study also associated
the presence of some genus with disease severity. In both systemic
sclerosis cohorts, Clostridium was more abundant in patients
with low gastrointestinal symptom severity, Lactobacillus was
more abundant in patients with mild constipation and Prevotella
was more abundant in patients with moderate to severe
gastrointestinal symptom severity. Further research will elucidate
the role and molecular pathways in which these genders
contribute to disease pathogenesis (Volkmann et al., 2017).
Even though, there is information relative to the influence
of intestinal microbiota over skin autoimmune diseases, there
are data that make these pathologies more complex. Therefore,
an influence of skin microbiota over the skin autoimmune
diseases remains to be demonstrated (Sanford and Gallo, 2013;
Statnikov et al., 2013; Tett et al., 2017). Briefly scientific work
that relates skin microbiota with skin autoimmune diseases
will be discussed due to the importance of the skin as a
physical barrier that constantly interacts with factors from the
environment, such as solar irradiation, grades of humidity or
dryness and microorganisms. While a wide range of microbes
inhabit the skin, the principal residents microbiota belong to
one of these phyla: Actinobacteria, Bacteroidetes, Firmicutes,
or Proteobacteria. Interactions between these microorganisms
at the skin and the immune system have been suggested to
influence tissue integrity and homeostasis (Sanford and Gallo,
2013). Similar to what happens in the gut, skin dysbiosis
has been postulated to contribute to the pathology of diverse
skin autoimmune diseases (Zeeuwen et al., 2013) like psoriasis,
psoriasis arthritis and vitiligo (Gao et al., 2008; Castelino et al.,
2014; Ganju et al., 2016). Studies related to chronic plaque
psoriasis, the most common form of psoriasis, have shown that
the composition of the microbiota both with skin lesions or not
differed of healthy skin (Gao et al., 2008; Alekseyenko et al.,
2013). Gao et al. showed that Firmicutes were the most abundant
and diverse phylum present in the psoriatic patients with skin
lesions (relative abundance of 46.2%) as compared to those that
did not display lesions (39%) and with healthy subjects (24.4%)
(Gao et al., 2008). In contrast, Actinobacteria has lower relative
abundance in psoriatic patients with lesions (37.3%) compared
to individuals with healthy skins (47.6%) (Gao et al., 2008). The
phylum of Proteobacteria was less frequent in psoriatic patients
(11.4%) as compared to subjects with healthy skin (21.9%).
Alekseyenko et al. described three distinct types of bacteria
from their data about the relative abundance of major phyla
present in the skin,Actinobacteria, Firmicutes, and Proteobacteria
(Alekseyenko et al., 2013). These results are consistent with
some of the findings described above. Proteobacteria dominate
the cutaneotype 1 they described, while the cutaneotype 2 has
higher relative abundance of Actinobacteria and Firmicutes.
These authors associated the cutaneotype 2 with psoriasis status
in which the higher abundance of Firmicutes coincides with the
results by Gao et al. (2008). The differences in the results could
be attributed to as to where the sample was obtained from, as
it has been demonstrated that skin microbial composition is
dependent on the area of the body that is analyzed (Grice and
Segre, 2011). Both studies provide evidence that skin microbiota
composition is different in patients with psoriasis as compared
to healthy controls. Nevertheless, the physiological meaning of
these differences has yet to be defined.
The most recent study to date related to psoriasis is a
metagenomic analysis that focused on the less explored diversity
of the skin microbiota and provided evidence that these less
characterized species inhabiting the skin might be relevant in
disease pathogenesis. In this study, an increase in members of the
genus Staphylococcus was associated to development of psoriasis
(Tett et al., 2017).
The skin microbiota is not the only microbial compartment
that has been associated to psoriasis pathogenesis. In a murine
model of imiquimod-induced psoriasis-like skin inflammation,
germ-free, and oral antibiotic-treated mice showed milder skin
inflammation as compared to conventional reared mice, along
with a decrease in γδTCR and Th17 cells in draining lymph
nodes and spleen. These cells are essential components of the
IL-23/Th17 axis, which happens to be the main axis in psoriasis
pathogenesis. These results suggest that the absence ofmicrobiota
or an alteration in their composition caused by antibiotic
treatment can decrease the pro-inflammatory T cell response
and thus diminish the severity of the imiquimod-induced skin
inflammation (Zakostelska et al., 2016). Interestingly, in humans,
a link between psoriasis and Crohn’s disease has long been
acknowledged (Hughes et al., 1983) and discussed extensively
in previous articles (Najarian and Gottlieb, 2003). Finally, a
recent study characterized for the first time the skin microbial
composition of patients with the autoimmune disease vitiligo
(Ganju et al., 2016). The data obtained were used to characterize
a core skin microbiome for a lesional and non-lesional skin
(Ganju et al., 2016). Methylobacterium constitutes a genus
exclusive to lesional skin while Anaerococcus, Microbacterium,
Streptophyta, and Nocardiode are exclusive to non-lesional skin
(Ganju et al., 2016). It remains unclear whether the microbiota
differences between groups are a cause or an effect of altered
skin physiology of the depigmented patches. Therefore, further
research is required to define the contribution of the bacterial
component to the pathology of vitiligo (Ganju et al., 2016).
Compared to the vast information about the role of microbiota
in systemic autoimmune diseases, the contribution of intestinal
microbiota to skin disease conditions has not been fully explored
and requires further research.
AUTOIMMUNITY AND MICROBIOTA IN
PSYCHIATRIC DISORDERS
Psychiatric disorders have complex etiologies likely resulting
from environmental interactions with genetic factors (Tsuang,
2000; Chaste and Leboyer, 2012). Recently, comorbid immune
system dysregulations have emerged as a relevant etiological
agent in several psychiatric disorders, raising the concept
that autoimmunity might be an important contributing
factor (Severance et al., 2016). This notion is supported by
occurrence of brain inflammation-induced psychosis and
autoimmune encephalitis, such as the anti-NMDA receptor
encephalitis. This latter disease is characterized by the presence
of autoantibodies against the N-methyl-D-aspartate receptor
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(NMDAR), a glutamatergic receptor in the brain involved in
synaptic transmission (Guasp and Dalmau, 2017). Symptoms
include a range of psychotic symptoms early in the course of
the disease followed by neurologic deterioration and ultimately
protracted cognitive and behavioral deficits (Dalmau et al.,
2011). Remarkably, approximately 80% of patients recover
with immunotherapy directed to remove the antibodies
and antibody-producing plasma cells (Dalmau et al., 2017).
Consistently with this notion, various autoantibodies have been
detected in subgroups of schizophrenic patients (Pearlman
and Najjar, 2014). In particular, meta-analyses have suggested
that schizophrenic patients are three times more likely to have
high levels of anti-NMDAR antibodies as compared to healthy
controls (Pearlman and Najjar, 2014). Recently, Schwarz et al.
analyzed fecal microbiota from a small cohort of patients with
first-episode psychosis (FEP) (Schwarz et al., 2017). Interestingly,
Lactobacillus and Bifidobacterium were increased in FEP
patients and correlated with the psychotic symptoms severity
(Schwarz et al., 2017). Although up to date this is the only
report associating changes in the microbiota with psychotic
severity in patients, it was also reported that autistic children
show increased amounts of Lactobacillus in their intestinal
microbiota (Adams et al., 2011; Schwarz et al., 2017). At family
level, Schwarz et al. observed a decreased in the Veillonellaceae
family an alteration of the microbiota composition that was also
observed in depressive patients (Jiang et al., 2015).
As the largest organ of the immune system, the GI tract serves
as an interface between the environment and the host. Therefore,
alterations in gut cellular processes may influence immune
homeostasis. Data generated to date suggest that increased
intestinal permeability and alterations in the gut microbiota
composition are strongly associated with psychiatric disorders
and could represent potential sources of immune functional
impairment (Fiorentino et al., 2016; Esnafoglu et al., 2017;
Stevens et al., 2017). Gut microbiota seems to play a critical role
in the bidirectional communication between the gastrointestinal
tract and the CNS. In addition to regulating gastrointestinal
functions, this microbiota-gut-brain axis has been shown to
modulate brain functions, such as emotional behavior and stress-
related responsiveness (Diaz Heijtz et al., 2011). The mechanisms
implicated in these pathways, although not entirely characterized,
involve humoral and/or neural route, such as the vagus nerve (De
Palma et al., 2014). An involvement of the vagus nerve in the
communication between the gut and the brain was supported by
the observation that vagotomy abrogated the decrease of anxiety-
and depression-related behavior induced by the probiotic
L. rhamnosus in mice (Bravo et al., 2011). These observations
suggest a close relationship between the different components of
the gut-brain axis, several probiotics used in animal models have
shown their efficacy with combined and correlated beneficial
effects on the GI tract, such as intestinal barrier strengthening,
HPA axis activation and behavior, including social interaction,
anxiety, and exploratory behavior (Hsiao et al., 2013; Vanhaecke
et al., 2017). On the other hand, mice exposed to antibiotics
to alter the established microbiota, showed an increased in
explorative behavior associated with an enhanced level of brain-
derived neurotrophic factor (BDNF), an important growth
factor for neuronal survival and synaptic plasticity (Bercik
et al., 2011). However, another mouse strain exposed to
a different antibiotic mixture induced a different behavioral
phenotype consisting of an increased depressive-like behavior
and altered social interaction, which was associated with reduced
level of hippocampal BDNF activity. These data suggest that
mouse strains or antimicrobial regimen can differently influence
microbiota composition and in turn differently affect behavior
(Guida et al., 2017). The use of the probiotic Lactobacillus casei
DG in these animals was able to restore the behavioral phenotype
and BDNF levels similar to controls (Guida et al., 2017).
Interestingly, a decreased serum BDNF levels were observed
in patients with major depressive disorders (Pedrotti Moreira
et al., 2017) and pharmacological treatment that increases BDNF
levels proved to be beneficial for depressive patients (Gupta
et al., 2016). Along with the depressive-like behavior, mice
exposed to antibiotics showed a marked dysbiosis characterized
by a loss of bacterial diversity, an increase in Protebacteria and
Actinobacteria and a decrease in Bacteroidetes and Firmicutes.
The probiotic treatment was not able to restore this bacterial
phenotype, but promoted the increase of Lachnospiraceae, a
fiber-degrading and SCFA producer (Guida et al., 2017). In
humans, either a decrease or an increase of Lachnospiraceae has
been correlated with major depressive disorders (Naseribafrouei
et al., 2014; Fung et al., 2017), indicating that there is still a
controversy about microbiota composition in this pathology.
Such a discrepancy could probably result from the influence
of external factors (i.e., diet) between the patients cohorts
used in these studies. The causal link of microbiota on GI
and brain dysfunction has recently been shown for irritable
bowel syndrome (IBS), a common intestinal disorder often
accompanied by comorbid anxiety (De Palma et al., 2017).
Colonization of germ-free mice with fecal microbiota from
IBS patients induced altered GI transit, intestinal barrier
dysfunctions, and anxiety-like behavior, suggesting a role for
the gut microbiota in the expression of IBS (De Palma et al.,
2017). The importance of microbiota has also been highlighted in
neurodevelopmental disorders, such as autism spectrum disorder
(ASD). In mice, pregnant animals exposition to poly(I:C)
triggers a maternal immune activation that can cause in the
offspring to atypical social and repetitive behavior reminiscent
of ASD-related behavior. The mechanisms leading to behavioral
abnormalities in the offspring required a particular type of
maternal bacterium, the segmented filamentous bacteria (SFB),
which induces intestinal TH17 cells producing IL-17 (Kim et al.,
2017). Interestingly, induction of TH17 response by SFB has been
shown to modulate gene expression of enteric neurons, which in
turn influences microbiome/immune system crosstalk (Yissachar
et al., 2017). Besides behavioral abnormalities, offspring from
poly(I:C)-treated mice also develop GI symptoms, changes in gut
bacterial population and intestinal barrier defects, as reported in
some patients with ASD (Horvath and Perman, 2002). Treatment
of the offspring with B. fragilis induced a remodeling of the
microbiota composition ameliorated GI symptoms and reduced
repetitive behavior. These preclinical results stimulated the
development of pilot clinical studies using microbiome-driven
therapies for ASD. Although not controlled and double-blinded,
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a clinical trial based on microbiota transfer of healthy donors
in 7–16 years old children with ASD showed improvements
in GI symptoms and in social and communication skills that
are associated with bacterial community changes (Kang et al.,
2017). Similarly, probiotic supplementation with Bifidobacteria
and Lactobacillus species in 5–9 years ASD children modified the
fecal microbiota composition and improved both GI symptoms
and behavior (Shaaban et al., 2017). However, these studies
were performed with a small number of patients, and wide-scale
randomized controlled trials are needed to critically confirm the
efficacy of probiotics in ASD. The use of probiotics ormicrobiota-
derived metabolites that could selectively or simultaneously act
on the different components of the microbiota-gut-brain axis
raises alternative new treatments for CNS disorders. However,
more information is still required to better understand the
influence of the microbiota on CNS pathogenesis and to
delineate the cellular and molecular mechanisms involved in the
communication betweenmicrobiota, the gut, and the brain. Also,
the implications of intestinal dysbiosis in the etiology and/or
pathophysiology of brain diseases remain to be further defined
and represent a major challenge for translational research.
EXTERNAL FACTORS THAT INFLUENCE
THE MICROBIOTA
Microbiota is established by many factors that determine
the characteristics for each individual, including genetic
predisposition, an inheritance from the mother since the fetus
is forming until breastfeeding and environmental factors, such
as diet, culture, and geographic location (Yatsunenko et al.,
2012). However, when there is an imbalance of microorganism’s
populations present in the gut, known as dysbiosis, many
problems at the systemic level are triggered. This situation may
cause an incorrect nutrient absorption, favor weight alterations
and enhance some immune system diseases (Degruttola et al.,
2016).
Diet is one of the important factors affecting the composition
of microbiota in humans (Conlon and Bird, 2014; Sonnenburg
and Backhed, 2016). The first major change in diet that humans
experience is when the consumption of solid food begins.
At this stage, microbiota composition and abundance suffer
significant modifications, such as a decrease of Bifidobacteria and
Enterobacteria (Fallani et al., 2011). This process occurs due to
the new substrates that are available in the gut, leading to the
proliferation of certain types of microbes (Fallani et al., 2011;
Davis et al., 2017; Wampach et al., 2017). Later in life, each time
that diet changes this phenomenon takes place, promoting the
growth of somemicroorganismsmore than others (Ottman et al.,
2012; Odamaki et al., 2016; Sonnenburg and Backhed, 2016). In
turn, this evolving microbiota will modulate the development
and function of the immune system (Round and Mazmanian,
2009; Conlon and Bird, 2014; Kabat et al., 2014). However,
microbiota analyses highlighted that although after a month of
receiving a traditional diet, the composition of the microbiota
took 1 year to change and be similar to the one found in other
people with the same diet (Claesson et al., 2012).
FIGURE 2 | Influence of the gut microbiota in non-intestinal diseases. Gut dysbiosis induced by external factors as diet, infections, or antibiotic overuse lead to an
inflammatory response that influence the outcome of several autoimmune diseases as Grave’s disease, Hashimoto’s Thyroiditis, Multiple Sclerosis, SLE, and type1
diabetes. It has also been observed an important role in skin related autoimmune diseases as Psoriasis. Moreover, the evidences in the literature support that gut
microbiota can influence CNS disorders like autism, depression, and schizophrenia.
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Human studies have shown that there is a correlation in
elderly between the microbiota location and diet, which can
influence their health (Claesson et al., 2012). Additionally,
analyses of microbiota composition had shown four different
dietary groups and found that diet based on “low fat-high
fiber” was associated with a more diverse microbiota. A study
performed with C57BL/6mice fed with high-fat diet was aimed at
evaluating whether inflammation was due to microbiota changes
or cytokines production. Results have shown that microbiota
underwent changes 8 weeks after the treatment started, but
increased IFNγ and TNF-α cytokines were only detected 16
weeks after administration of a high-fat diet (Guo et al., 2017).
These observations underscore the importance of microbiota
and corroborate the ability of diet to modulate microbiota
composition.
Additionally, evaluation of the feces obtained from three
different dietary groups ovo-lacto vegetarian, vegans, and
omnivores, showed differences in microbiota composition
(Ferrocino et al., 2015). Findings showed that B. fragilis group
was diminished on ovo-lacto vegetarian and vegan volunteers,
which is associated with low consumption of protein and animal
fat (Wu et al., 2011). Also, a significant reduction for the loads for
Lactic Acid Bacteria (LAB) was observed for the dietary groups
ovo-lacto vegetarian and vegan, which may be due to the absence
or low intake of some food such as cheese and yogurt (Zimmer
et al., 2012).
Gluten-free diet is worldwide used for patients with celiac
disease (CD), which is a chronic enteropathy caused mainly
by gluten intolerance. It has been shown that the intestinal
microbiota can be modified by a gluten-free diet: two of the
groups that are reduced by such a diet are Lactobacillus and
Bifidobacterium, which are considered as part of the group
of healthy bacteria (De Palma et al., 2009; Lorenzo Pisarello
et al., 2015). In contrast, some opportunistic bacteria from
Enterobacteriacea family are increased as a result of gluten-free
diets (De Palma et al., 2009; Lorenzo Pisarello et al., 2015). One
possible explanation for these changes in the microbiota is the
low carbohydrate intake due to the restrictions imposed by the
gluten-free diet. Healthy bacteria usually use carbohydrates for
their metabolism, which are needed for the colonization and
fermentation inside the gastrointestinal tract (Sanz, 2010).
A diet that low in carbohydrates accessible for microbiota
results in low levels of production of Short Chain Fatty Acids
(SCFA) produced by bacteria from the microbiota. Butyrate,
propionate, and acetate can modulate immune system by
controlling inflammation and promoting an anti-inflammatory
environment in the gut (Maslowski et al., 2009; Arpaia et al.,
2013). However, when the diet undergoes a detrimental change,
the abundance of these beneficial bacteria decreases and therefore
SCFA production is reduced. Alteration of SCFA is common in
obesity, celiac disease, and Type 2 Diabetes, because it is known
that their action ameliorates the disease (Lin et al., 2012; Hong
et al., 2016; Lerner et al., 2016).
Consistently with this notion, the Ma-Pi2 diet a diet rich
in carbohydrates, whole grains and vegetables was shown to
ameliorate dysbiosis and increment the diversity of microbiota
TABLE 1 | Alterations observed in the microbiota in non-intestinal autoimmune
diseases.
Autoimmune
disease
Observation References
Grave’s disease : yeast
Presence of antibodies against
Y. enterocolitica and H. pylori.:
Bacteroides
Covelli and Ludgate,
2017
Kohling et al., 2017
Indigo, 2017
Hashimoto’s
thyroiditis (HT)
Dysbiosis
Altered intestinal morphology
: intestinal permeability
Sasso et al., 2004
Multiple Sclerosis
(MS) Murine EAE
model Human
:
Sutterella
: intestinal permeability
: Zonulin expression
Th17 > Treg
Dysbiosis:
Bacteroides:
Parbacteroides:
Prevotella:
Lactobacillus
: Akkermansia:
Blautia:
Ruminococcus:
Bifidiobacterium
Berer et al., 2017
Nouri et al., 2014
Sturgeon and Fasano,
2016
Nouri et al., 2014
Chen et al., 2016
Jangi et al., 2016
Freedman et al., 2017
Systemic Lupus
Erythematosus
(SLE) Mouse
model of SLE
Human
:
La ctobacillus
: Lachnospiraceae
Dysbiosis:
Firmicutes:
Bacteroides
Hevia et al., 2014
Zhang et al., 2014
Psoriasis : Firmicutes:
Actinobacteria
: Proteobacteria (Cutaneotype 1)
: Actinobacteria (Cutaneotype 2)
: Firmicutes (Cutaneotype 3)
: Staphylococcus
Gao et al., 2008
Alekseyenko et al., 2013
Tett et al., 2017
Psoriatic arthritis
:
Akkermansia:
Ruminococcus:
Pseudobutyrivibrio
Scher et al., 2015
Scleroderma : Firmicutes:
Bacteroides
: Clostridium
: Lactobacillus (mild
gastrointestinal symptoms)
: Prevotella (moderate to severe
gastrointestinal symptoms)
Volkmann et al., 2017
Vitiligo Methylobacterium in lesional skin
Anaerococcus in non-lesional skin
Microbacterium in non-lesional skin
Streptophyta (non-lesional skin)
Nocardiode (non-lesional skin)
Ganju et al., 2016
Type 1 Diabetes : intestinal permeability
: Zonulin
: Bacteroideaceae
: Blautia
: Rikenellaceae
: Ruminococcus
: Sreptococcus
Secondulfo et al., 2004;
Sapone et al., 2006;
Maffeis et al., 2016
Sapone et al., 2006
De Goffau et al., 2013
Kostic et al., 2015
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in Type 2 Diabetes patients, as compared to untreated
patients. Also, abundance of SCFA producers increased, such
as Bacteroides, Dorea, and Faecalibacterium. Furthermore, the
implementation of this diet has shown a potential role in the
recovery of metabolic control in Type 2 Diabetes (Fallucca et al.,
2014; Candela et al., 2016).
Overuse of Antibiotic Treatments
Overuse of antibiotics may cause a significant imbalance in
microbiota and a disruption of the natural interaction between
the microorganisms. One of the most important characteristics
of a normal microbiota is the capacity to compete out infectious
pathogens (Kamada et al., 2013a). Therefore, microbiota removal
by antibiotics may allow the detrimental growth of pathogenic
bacteria populations, increasing the probability of an infection.
Additionally, antibiotics not only kill pathogens but also
beneficial bacteria, eliminating as well the positive effect of the
latter. Microbiota modulates the immune response through the
molecules it produces, so if beneficial microorganisms decrease,
a decrease in the modulation of the immune system can also be
observed (Langdon et al., 2016).
In response to a constant exposure of an antibiotic,
microorganisms can acquire genetic resistance, leading to an the
increment of multi-drug resistance microorganisms (Jernberg
et al., 2007), which can become a major public health problem
due to the lack of new treatments capable of eliminating these
bacteria. In the last years, many cases of infection caused by
multi-drug resistant bacteria were reported and this number
is expected to increase (Karam et al., 2016; Lee et al., 2016).
The effects of overuse of antibiotics can be treated but not
reversed. Restoration of the microbiota can take months or
even years, but it will not be able to become the same as
before (Jernberg et al., 2007, 2010). Importantly, it has also been
described that newborns whosemothers have received antibiotics
perinatally have a different microbiota composition, as compared
to newborns whose mother have not been treated (Fallani et al.,
2011). Due to the importance of first microorganisms in the gut
of newborn, these changes in microbiota caused by excessive use
of antibiotics may have long-term consequences (Langdon et al.,
2016).
Interestingly, recent findings have highlighted the natural
presence of antibiotic resistance genes in microbiota and their
differential occurrence according to diet. Microbiota changes
observed in ovo-lacto vegetarian and vegan diets, as compared to
omnivores diet, are related to the presence of antibiotic resistance
genes. A study performed with 144 volunteers found the presence
of 12 antibiotic resistance genes in their microbiota. Among
these genes, the occurrence of erm(A) (Erythromycin resistance
methylase gene) has been exclusively detected in the feces of
vegan subjects, which also show a low abundance of tet(K)
(Tetracycline efflux protein), as compared to the genes present
in the feces of omnivores. Interestingly, another antibiotic
resistance gene with a higher occurrence observed in the feces of
omnivores was van(B) (Vancomycin resistance gene; Milanovic
et al., 2017).
CONCLUSIONS
This review article discusses data supporting the influence of
the gut microbiota over non-intestinal autoimmune diseases.
The central theme of this review is the intestine in which
two important actors, microbiota and the immune system
are controlling the response to non-intestinal autoimmune
diseases (Figure 2, Table 1). Not much is known about the
mechanisms of the interaction between microbiota and the
immune system. However, today it is possible to identify
certain members of the microbiota that regulate, balance or
unbalance the immune response of the host. The current
evidence supports the notion that changes or alterations of the
microbial species that form part of the intestinal microbiota
will affect the balance of Tregs and Th17 cells at the intestine,
which could modify the immune response of non-intestinal
autoimmune diseases. The experimental evidence suggesting
that the cytokines secreted from Treg and Th17 will determine
and influence non-intestinal autoimmune responses. It could
also be possible that cells of the immune system located
at the intestine could to move other organs to establish or
modify an autoimmune response. The major message of this
review is that the abundant data support the notion that the
intestine is a critical organ the appropriate immune balance
and for the prevention of non-intestinal autoimmune diseases.
The key point is that by modifying the intestinal microbiota
of a patient that suffers non-intestinal autoimmune disease it
might be possible to improve the outcome of such illness.
Interestingly, by modifying the diet it might be possible
to improve the intestinal microbiota to promote an anti-
inflammatory response of a patient suffering from autoimmunity.
Thus, the scientific community has paid attention to the potential
therapeutical benefits of manipulating the composition of the
gut microbiota through oral administration of probiotic or
modified organisms expressing selected self-antigens to treat
these non-intestinal autoimmune diseases. Work remains to be
done in order to fully understand the complex mechanisms of the
intestinal microbiota that can impact non-intestinal autoimmune
diseases.
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